Pre COVID-19 pandemic no one could have imagined a pandemic of such magnitude could happen across the globe bringing the world to a halt. Evidently, the current sanitary situation and travelling restrictions across continents has brought onsite audits to a standstill. However, the qualification process cannot be compromised so what options do pharma companies have…
Some of the requirements to conduct on-site GMP audits are therefore clear, for example in Article 46(f) EU Directive 2001/83/EC:
“the holder of the manufacturing authorisation shall verify compliance by the manufacturer and distributors of active substances with good manufacturing practice and good distribution practices by conducting audits at the manufacturing and distribution sites…”
Some of the options incorporated by the authorities or even the marketing authorisation holders is to have a distant assessment through remote desktop audits either through video conferencing or an audio communication. In April 2020 the EMEA authorities have already devised a questionnaire (question and answer document) which broadly addresses the remote distant assessment of manufacturer’s and cites examples of audits which can be conducted.
The pharmaceutical industry and marketing authorisation holders have little choice but to resort to remote desktop GMP verification. A distant assessment is therefore a possible way to assess manufacturer’s or CMO’s GMP compliance. The Qualified Person (QP) conducting desktop audit can clearly point out that distant assessments are not intended as a substitute for on-site inspections and that on-site inspections should be carried out as soon as circumstances permit. Decision should be based on an adequate, scientific and documented risk assessment.
For new sites too such distant assessments by the competent authorities can be an option and provisional GMP certificate can be issued based on the assessment outcome with a condition to allow the onsite GMP audits as soon as it becomes possible. Distant assessment and supplier qualification will certainly increase in the near future, but these qualifications cannot replace the onsite audit requirements.
Resources:
Notice to stakeholder’s questions and answers on regulatory expectations for medicinal products for human use during the covid-19 pandemic:
https://ec.europa.eu/health/sites/health/files/human-use/docs/guidance_regulatory_covid19_en.pdf
The pharmaceutical and biotechnology industries constantly seek innovative methods to enhance product stability, solubility, bioavailability and ease of use. Within this realm, CDMOs [Contract Development & Manufacturing Organizations] serve as invaluable partners in the development and production of high-quality drug products.
Chinese New Year 2024 is upon us, disrupting logistics from Asia starting Feb 10th. This event is expected to impact global shipping until Feb 21. Freight rates from Asia has skyrocketed with rates to the US surging by 3.5X and Europe by 6X.
Amid ongoing Red Sea diversions by shipping giants like Maersk, CMA, logistics managers are globally confronting a dual challenge of escalating ocean and air freight prices alongside cargo disruptions due to
Why will CM be the next generation on quality?
The Fifth International Conference on Chemicals Management (ICCM5) concluded on 30 September in Bonn, Germany, by adopting “a comprehensive global framework that sets concrete targets and guidelines for key sectors across the entire lifecycle of chemicals”.
In October, the People’s Republic of China celebrates its annual national holiday, known as Golden Week. Similar to Chinese New Year, the entire country is on holiday, resulting in business closures and a potential 14-day halt in production and transportation of manufactured goods.
The European Chemicals Agency (ECHA) has amended the Prior Informed Consent (PIC) Regulation, EU 64/2012, to add 27 pesticides and eight industrial chemicals into Annex I, bringing the total to 295. As a result, EU exporters are now required to notify their intentions to export them from 1 November onwards.
The global custom synthesis and manufacturing market was valued at US$271.33 billion in 2022. The market value is expected to reach US$474.94 billion by 2028.
The ocean freight industry is undergoing a massive transformation, as the technology and supply chain management tools are being improved by the day, impacting ocean freight rates.